Last reviewed · How we verify
Irinotecan + Carboplatin (irinotecan-carboplatin)
Irinotecan + Carboplatin (generic name: irinotecan-carboplatin) is a drug developed by Pfizer Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | irinotecan-carboplatin |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
- Anaemia
- Vomiiting
- Neutropenia
- Thrombocytopenia
- Nausea
- Neutrophil count decreased
- Abdominal pain
- Headache
- Diarrhoea
- Plastelet count decreased
- Cough
- Leukopenia
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas (PHASE1)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (PHASE1)
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) (PHASE1)
- A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Irinotecan + Carboplatin CI brief — competitive landscape report
- Irinotecan + Carboplatin updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Irinotecan + Carboplatin
What is Irinotecan + Carboplatin?
Irinotecan + Carboplatin (irinotecan-carboplatin) is a pharmaceutical drug developed by Pfizer Inc..
Who makes Irinotecan + Carboplatin?
Irinotecan + Carboplatin is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of Irinotecan + Carboplatin?
irinotecan-carboplatin is the generic (nonproprietary) name of Irinotecan + Carboplatin.
What development phase is Irinotecan + Carboplatin in?
Irinotecan + Carboplatin is in Phase 2.
What are the side effects of Irinotecan + Carboplatin?
Common side effects of Irinotecan + Carboplatin include Anaemia, Vomiiting, Neutropenia, Thrombocytopenia, Nausea, Neutrophil count decreased.
Related
- Manufacturer: Pfizer Inc. — full pipeline
- Compare: Irinotecan + Carboplatin vs similar drugs
- Pricing: Irinotecan + Carboplatin cost, discount & access